Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Liguria – page 63

810 clinical trials in Liguria, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Liguria at a glance
810
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

810 trials in Liguria

Open in trial search

IgA nephropathy

Not recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Breast cancer

Not recruiting

Study on Anastrozole, Letrozole, Exemestane, and Tamoxifen for Women Aged 70+ with Early Stage Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Anastrozole
  • Sponsor:University Of Florence

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Bronchiectasis+1

Not recruiting

Study on the Safety and Tolerance of BI 1291583 in Adults with Cystic Fibrosis Bronchiectasis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Study on Cannabidiol Oral Solution for Infants with Tuberous Sclerosis, Dravet Syndrome, or Lennox-Gastaut Syndrome Experiencing Uncontrolled Seizures

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cannabidiol
  • Sponsor:Jazz Pharmaceuticals Research UK Limited

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Novartis Pharma AG

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Asthma

Not recruiting

Study on Tezepelumab for Children Aged 5 to 11 with Severe Asthma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Liguria

What the registry says about research in the country

01 HIV Treatment Research

Clinical research focusing on early treatment switching strategies for HIV-1 infected individuals who have achieved viral suppression. The trials examine the effectiveness of transitioning from three-drug to two-drug antiretroviral therapy.

  • Viral Suppression Maintenance
  • Treatment Simplification
  • Long-term Safety Assessment

The study aims to evaluate a novel approach using dolutegravir/lamivudine combination therapy, potentially offering patients a more streamlined treatment regimen while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.